These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21768848)

  • 1. Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl.
    Lestishock L; Pariseau C; Rooholamini S; Ammerman S
    Obstet Gynecol; 2011 Aug; 118(2 Pt 2):443-445. PubMed ID: 21768848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaphylaxis from medroxyprogesterone acetate.
    Selo-Ojeme DO; Tillisi A; Welch CC
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decline in bone mineral density with stress fractures in a woman on depot medroxyprogesterone acetate. A case report.
    Harkins GJ; Davis GD; Dettori J; Hibbert ML; Hoyt RA
    J Reprod Med; 1999 Mar; 44(3):309-12. PubMed ID: 10202754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body weight and body composition of depot medroxyprogesterone acetate users.
    Dal'Ava N; Bahamondes L; Bahamondes MV; Bottura BF; Monteiro I
    Contraception; 2014 Aug; 90(2):182-7. PubMed ID: 24780631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mineral density in long-term depot medroxyprogesterone acetate acceptors.
    Taneepanichskul S; Intaraprasert S; Theppisai U; Chaturachinda K
    Contraception; 1997 Jul; 56(1):1-3. PubMed ID: 9306024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance with depot medroxyprogesterone acetate: a randomized, controlled trial of intensive reminders.
    Keder LM; Rulin MC; Gruss J
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 1):583-5. PubMed ID: 9757955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human vaginal histology in long-term users of the injectable contraceptive depot-medroxyprogesterone acetate.
    Bahamondes MV; Castro S; Marchi NM; Marcovici M; Andrade LA; Fernandes A; Bahamondes L
    Contraception; 2014 Aug; 90(2):117-22. PubMed ID: 24613369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate.
    Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L
    Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T; Evans M; Roberts H; Wattie D; Ames R; Reid IR
    BMJ; 1991 Jul; 303(6793):13-6. PubMed ID: 1830502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RETIRED: Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa).
    Black A; ;
    J Obstet Gynaecol Can; 2006 Apr; 28(4):305-308. PubMed ID: 16776909
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of pretreatment counseling on discontinuation rates in Chinese women given depo-medroxyprogesterone acetate for contraception.
    Lei ZW; Wu SC; Garceau RJ; Jiang S; Yang QZ; Wang WL; Vander Meulen TC
    Contraception; 1996 Jun; 53(6):357-61. PubMed ID: 8773423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
    Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
    Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone density in long term users of depot medroxyprogesterone acetate.
    Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
    Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral density testing, and bisphosphonate and oestrogen prescribing associated with depot medroxyprogesterone acetate utilization-The impact of the boxed warning.
    Eworuke E; Popat V; Moeny DG
    J Clin Pharm Ther; 2017 Aug; 42(4):483-494. PubMed ID: 28543135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability.
    Prabhakaran S; Sweet A
    Contraception; 2012 May; 85(5):453-7. PubMed ID: 22079605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception.
    Nelson AL
    J Reprod Med; 1996 May; 41(5 Suppl):391-400. PubMed ID: 8725701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.